Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets

Siarhei Khaletski/iStock via Getty Images The biggest pharmaceutical stock by market capitalisation, Eli Lilly (NYSE:LLY) continues its unabated upward journey. Not only has it more than doubled its price in the past year, but it’s up by 33.6% in the first quarter of 2024 (Q1 2024) as well. Here I look at whether there's more upside to it, especially as its market multiples are looking rather stretched now. Winning in the Diabetes market The company's gains in its diabetes segments certainly give room f ...